Status: Recruiting
Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS
Phase III trial evaluating the safety and efficacy of a single high dose (10 mg/kg) of liposomal amphotericin B for disseminated histoplasmosis in AIDS patients, in comparison to standard therapy (3 mg/kg of liposomal amphotericin B for two weeks) (INDUCTION trial).
Participants needed: 279
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Federal University of Health Science of Porto AlegreUpdated: Feb 4, 2025Locations: 5
Eligibility criteria
Adult patients admitted to the centers that will be part of the study [+4]
Refusal to participate in the trial [+11]